FDA Approves Brentuximab Vedotin for Previously Untreated Stage III or IV Classical Hodgkin Lymphoma

Approval is based on results from the ECHELON-1 trial

Source

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply